Archive for January, 2010

How does Genomics, Proteomics and Bioinformatics help in Target Discovery?

Sunday, January 31st, 2010

Like the title say, I would like to know how these helps in Target Discovery. Please be as clear as possible. I feel that the target is discovered based on “theory”. For example if you have a heartbeat disorder, you probably want to target the calcium channel. However, I dont see how genomics, proteomics and bioinformatics come in here. It’s more of like logic. Anyone can give any better examples and/or explain how it works to me. THanks.

The Medical Device R&D Handbook

Sunday, January 31st, 2010

Product Description
The Medical Device R&D Handbook presents a wealth of information for the hands-on design and building of medical devices. Detailed information on such diverse topics as catheter building, prototyping, materials, processes, regulatory issues, and much more are available in this convenient handbook for the first time. The Medical Device R&D Handbook also includes exclusive interviews with pioneers and leaders in the medical device industry, offering an insider’s pe… More >> The Medical Device R&D Handbook

The Vision (© Roche Diagnostics GmbH)

Sunday, January 31st, 2010

About Roche Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our website at www.roche.com. Über Roche Roche mit Hauptsitz in Basel, Schweiz, ist ein global führendes, forschungsorientiertes Healthcare-Unternehmen in den Bereichen Pharma und Diagnostika. Als weltweit grösstes Biotech-Unternehmen trägt Roche mit innovativen Produkten und Dienstleistungen, die der Früherkennung, Prävention, Diagnose und Behandlung von Krankheiten dienen, auf breiter Basis zur Verbesserung der Gesundheit und Lebensqualität von Menschen bei. Roche ist der weltweit bedeutendste Anbieter von in-vitro Diagnostika sowie von Krebs- und Transplantationsmedikamenten, nimmt in der Virologie eine Spitzenposition ein und ist ferner auf weiteren wichtigen therapeutischen Gebieten aktiv, darunter Autoimmun-, Entzündungs- und Stoffwechselkrankheiten sowie Erkrankungen des Zentralnervensystems. 2006 erzielte die Division Pharma einen Umsatz von 33,3 Milliarden Franken und die Division Diagnostics Verkäufe von 8,7 Milliarden Franken. Roche beschäftigt weltweit rund 75’000 Mitarbeitende und unterhält Forschungs- und Entwicklungskooperationen und strategische Allianzen mit zahlreichen Partnern. Hierzu gehören auch Mehrheitsbeteiligungen an Genentech und Chugai. Die Division Roche Diagnostics verfügt über ein in der Branche einzigartiges Spektrum an innovativen Testprodukten und Dienstleistungen für Forscher, Ärzte, Patienten, Kliniken und Labors auf der ganzen Welt. Für weitere Informationen besuchen Sie unsere Website www.roche.com.

Did Olympus already acquire Beckman Coulter in Malaysia?

Sunday, January 31st, 2010

I am curious as to the status of this principal?is this true?

Which of the following statements regarding proteomics is correct?

Sunday, January 31st, 2010

A. Proteomics is the study of protein interaction within a cell.
B. Proteomics involves the complete analysis of the prokaryotes.
C. Proteomics is a straightforward task that is technically simple.
D. Proteomics is the systemic study of the full set of proteins encoded by a genome.
E. Proteomics and genomics allows scientists to study life in an ever-increasing reductive approach.

Capsule Tech: Enterprise Medical Device Connectivity

Sunday, January 31st, 2010

Capsules Enterprise Connectivity Solution is the only solution that will truly adapts to the environment it operates in. Its design gives hospitals the option to deploy connectivity throughout the enterprise so that all departments, not just high acuity, can enjoy the value that device integration has to offer. And it completely integrates with existing or planned caregiver work processes and allows a facility to leverage existing technologies.

Live Proteomics

Friday, January 29th, 2010

How proteins can be identified in real time by labeling the translation machinery of the cell with fluorescent probes

How do medical device reps make so much money?

Friday, January 29th, 2010

I have heard of people who sell medical devices that make 500,000 dollars a year and more! How is that possible? How do you get those jobs? What are the best med device companies? What do you look at before taking a med device job?

Life Science Companies and the Fda: How Change Control Software Transforms a Combatant Fist Fight Into a Picnic in the Park

Friday, January 29th, 2010

When you consider the relationship a life science company shares with the FDA itâ??s easy to visualize the love/hate kinship of a parent and child. Itâ??s also simple to deduce who the parent might be. After all, the FDA Mama or Papa Bear has never been shy when it comes to playing by regulatory rules.

The Goals of Life Science and the Goals of the FDA: Mutually Compatible or Mutually Exclusive?

The goals of a life science company are likely to include the development, manufacture and sales of the best and most useful biotech equipment, medical devices, drugs, etc. The goals of the FDA include safety, the transparent communication of possible dangers or uncomfortable side effects, and the viable effectiveness of products produced. Each set of goals is noble and in theory supports the goals of the other. In practice however, the goals of these separate institutions seem almost mutually exclusive.

Change Control Software: Middle Ground for Two Separate Powers

Like most solutions to apparently irreparable problems, the solution that allows both life science companies and the FDA to find a cheerful middle ground is the solution that benefits both organizations. This solution includes the implementation and use of change control software. Change control software is valuable for the simple reason that it allows life science companies to artfully manage (without spending ridiculous man-hours) those changes that occur at any stage of a productâ??s development or manufacturing processes. Documentation, routing, tasks and employee accountability are also concerted via a solid change control software solution.

The benefits of a change control software solution are many but to truly understand these benefits itâ??s beneficial to first understand the problems that often maintain many life science professionals in a state of â??regulatedâ? frustration.

The Problems

Among the problems that lie within the walls of many life science companies is the problem of change management processes that are controlled 1) manually or 2) with a hybrid/decentralized solution. Most companies simply want to save their hard earned ROI, but when considered carefully itâ??s easy to see that manual and/or hybrid solutions wonâ??t save companies money in the long run, and in addition, present a variety of problems that might have managed to stump even Solomon the wise.

Manual and Hybrid Solutions: Problems that Contribute to Greater Problems

Listed below are some of the problems that life science companies can avoid with a digitized and centralized change control software solution.

High Costsâ??Life science professionals may think they save money with a paper-based system but in all reality they spend a great deal to pay for the tedious man-hours spent on the manual routing of documents, the document approval process and on manual search and document retrieval (if the document can actually be found). A change control software solution however manages to automatically route documents, seek the appropriate approvals/electronic signatures, search for documents and retrieve them.

Validation Proceduresâ??The FDA requires that processes (this includes change processes) be validated. If a life science company has to validate their processes manually it can be a far greater challenge than some companies care to undertake. Electronic validation presents a far more effective alternative that saves time, money, and effort. In the long run, manual validation can also cost more than a centralized solution. When searching for change control software, ask the software sellers if automated validation services are available.

No Centralized Locationâ??A paper-based system doesnâ??t allow life science professionals to maintain, protect and organize documents in one digitized and centralized location. A commendable change control software solution digitizes and centralizes information so that life science associates can find the organized information they needâ??when they need it. A good change control software solution will also manage almost any type of file required throughout any of the GxP processes.

Document Revision Processesâ??When change inevitably occurs the manual document revision process can be faulty in the extreme. Life science employees will unfortunately be subjected to manual searches for documents, and will be required to manually make changes on documents or SOPs. A good change control software solution however can provide revision control that is automatic and centralized so that once submitted, documents can be routed and approved quickly and effectually. Change tracking will also be automatic.

Also, when searching for the change control solution that will fit the needs of a life science company, professionals should look for a solution that is 1) customizable to their needs and that 2) require form explanations for changes that are being made. Accountability, after all should be an important aspect of change control.

A Picnic in the Park

Change control can take life science professionals one step further to a change management process that could potentially be compared to a picnic in the park.

Marci Lynn Crane

Marci Crane is a copywriter for MasterControl in Salt Lake City, UT. For more information in regards to change control, software please feel free to contact a MasterControl representative.

Roche Diagnostics Corporate Film

Friday, January 29th, 2010

Roche Diagnostics Corporate Film